Abstract The gene encoding CYP102A2, a novel P450 monooxygenase from Bacillus subtilis, was cloned and expressed in Escherichia coli. The recombinant enzyme formed was purified by immobilised metal chelate affinity chromatography (IMAC) and characterised. CYP102A2 is a 119-kDa self-sufficient monooxygenase, consisting of an FMN/FAD-containing reductase domain and a heme domain. The deduced amino acid sequence of CYP102A2 exhibits a high level of identity with the amino acid sequences of CYP102A1 from B. megaterium (59%) and CYP102A3 from B. subtilis (60%). In reduced, CO-bound form, the enzyme shows a typical Soret band at 449 nm. It catalyses the oxidation of even-and odd-chain saturated and unsaturated fatty acids. In all reactions investigated, the products were the respective ω-3, ω-2 and ω-1 hydroxylated fatty acids. Activity was highest towards oleic acid (K M =17.36±1.4 μM, k cat =2,244 ±72 min ). Comparison of a CYP102A2 homology model with the CYP102A1 crystal structure revealed significant differences in the substrate access channels, which might explain the differences in the catalytic properties of these two enzymes.
Introduction
Cytochrome P450 monooxygenases (P450s or CYPs) are heme-containing proteins present in all kingdoms of life (Lewis 1996) . CYPs play a pivotal role in the synthesis and metabolism of secondary metabolites, such as prostaglandins (Berg et al. 2003) , leucotrienes and thromboxanes (Kupfer and Holm 1989) , steroid hormones (el-Monem et al. 1972; Sallam et al. 1977) , insect and plant hormones (Durst and O'Keefe 1995; Feyereisen 1999) and some colours and odours in plants (Holton et al. 1993) . P450 monooxygenases in mammalian liver function as detoxification system (Goldstein and Faletto 1993) by activating water-insoluble or barely water-soluble compounds for further degradation and elimination. As CYPs are able to introduce molecular oxygen regiospecifically and enantioselectively into allylic positions, double bonds and even into non-activated C-H bonds, they have recently been targeted as biocatalysts for the industrial production of fine chemicals, such as pharmaceuticals or polymer building blocks. From a technical point of view, bacterial CYPs are more promising than those from plants and animals, as they are mostly soluble and not membrane-associated. They also show much higher reaction rates, compared with CYPs from other sources, and they exhibit a relatively high stability. Activity and selectivity of bacterial CYPs can effectively be changed and/or improved by methods of site-directed mutagenesis or directed evolution (Appel et al. 2001; Salazar et al. 2003; Seng Wong et al. 2004) . Great efforts are presently being made to improve the storage and operational stability of bacterial P450 enzymes (e.g. tolerance towards organic solvents or hydrogen peroxide; Maurer et al. 2003; Salazar et al. 2003; Seng Wong et al. 2004) .
Among the members of the cytochrome P450 family, the monooxygenase from Bacillus megaterium (CYP102A1 or P450 BM-3) exhibits the highest turnover frequency (>1,000 min
−1
). It is a catalytically selfsufficient monooxygenase which contains a heme domain and a flavin reductase domain on a single polypeptide chain (Narhi and Fulco 1986; Wen and Fulco 1987) , whereas the electron transport chain from NAD(P)H to heme iron in most CYPs involves separate electron transport proteins. From a technical point of view, such self-sufficient bacterial P450 monooxygenases facilitate in vitro applications, as they do not require any separately added electron transport partners for function.
Analysis of the genome of the Gram-positive bacterium B. subtilis (Kunst et al. 1997) revealed eight candidate genes which potentially code for P450 monooxygenases.
Two of these genes-CYP102A2 and CYP102A3-code for single-peptide monooxygenases, comprising both a heme and an FAD/FMN-containing reductase domain, and demonstrate a notable sequence similarity to CYP102A1. CYP102A3 has already been successfully cloned, expressed, characterised and modified through site-directed mutagenesis in our laboratory (Lentz et al. 2004a) . CYP102A3 is involved in the hydroxylation of unsaturated, saturated and branched-chain fatty acids (Gustafsson et al. 2001; Lentz et al. 2004b) .
We now report the cloning, heterologous expression and characterisation of CYP102A2 from B. subtilis with a focus on its substrate spectrum, kinetic parameters and stability. The products of this enzyme-hydroxylated or epoxidised fatty acids and their derivatives, especially if enantiomerically pure-might find applications in the preparation of fine chemicals for the synthesis of polymers, flavours, fragrances or pharmaceuticals.
Materials and methods

Chemicals
All chemicals were of analytical grade or higher quality and were purchased from Fluka (Buchs, Switzerland) or Sigma (Deisenhofen, Germany). Odd carbon number fatty acids were obtained from Cognis (Düsseldorf, Germany).
Strains, plasmids and growth conditions
Escherichia coli strain DH5α [F − ; supE44; lacU169; (Φ80d lacZ M15) hsdR17; recA1; endA1] was purchased from Clontech (Palo Alto, Calif., USA), E. coli strain BL21 (DE3) {[B; F − ; ompT hsdS B (r B − m B − ); dcm; galλ(DE3)]} and the pET28b+ vector were purchased from Novagen (Madison, Wis., USA) and B. subtilis strain 168 from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany; DSMZ 402). E. coli strains were grown at 37°C with shaking (150 rpm) in Luria-Bertani (LB) or Terrific broth (TB) medium supplemented with 30 μg ml −1 kanamycin. B. subtilis was cultivated in LB medium at 30°C with shaking at 150 rpm overnight.
Cloning of the cyp102A2 gene (yfnJ gene) from B. subtilis Genomic DNA from B. subtilis was obtained by phenol/ chloroform extraction and subsequent isopropanol precipitation. Amplification of the gene was performed by PCR using the oligonucleotide primers 5′-GATGGATCCTAT-GAAGGAAACAAGCCCGAT-3′ and 5′-CTAGAGCTCT-TATATCCCTGCCCAGACATC-3′. Nucleotides in italics represent BamHI and SacI restriction sites, which are introduced upstream of the cyp102A2 start codon and downstream of the stop codon. The PCR fragment was digested with BamHI and SacI and ligated into the corresponding site of the dephosphorylated pET28b+ vector, resulting in pET28CYP102A2. E. coli transformed with this plasmid were plated on LB agar containing 30 μg ml −1 kanamycin. The integrity of the cloned cyp102A2 gene was verified by DNA sequencing.
Expression and purification of CYP102A2
Cultures were grown in 2-l flasks containing 400 ml TB medium supplemented with 30 μg ml −1 kanamycin at 37°C with shaking (150 rpm). When the optical density at 578 nm was 1.0, the expression was induced by 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and 33 mg of the heme-precursor δ-aminolevulinic acid was added. Expression was carried out at 25°C with shaking (120 rpm) overnight. Cells were harvested by centrifugation at 10,000 g for 20 min at 4°C and resuspended in 50 mM potassium phosphate buffer (pH 7.5) containing 500 mM sodium chloride, 5 mM imidazole and 0.1 mM phenylmethylsulfonyl fluoride. Cells were disrupted by sonication on ice (5×1 min, output control 4, duty cycle 40%, W250 sonifier; Branson, Dietzenbach, Germany) and the cell debris was removed by centrifugation at 37,000 g for 30 min. The N-terminally attached His 6 -tag allowed purification by immobilised metal chelate affinity chromatography (IMAC), utilising a Ni-NTA-resin (Qiagen, Germany). The column-bound enzyme was washed with 50 mM potassium phosphate buffer (pH 7.5) containing 500 mM sodium chloride and 50 mM imidazole. Elution was performed by increasing the imidazole concentration to 200 mM. Imidazole and sodium chloride were removed by dialysis against 50 mM potassium phosphate buffer (pH 7.5) overnight. The purity of the enzyme was estimated by SDS-PAGE, using 10% polyacrylamide running gels (Laemmli 1970) . Enzyme samples were supplemented with 50% glycerol and stored at −20°C until use.
CYP102A2 concentration measurement and absorption spectra Absorption spectra, NADPH oxidation and CO difference spectra were measured on an UV/vis spectrometer (Ultrospec 3000; Amersham Biosciences, Sweden). CYP102A2 concentrations were measured based on CO difference spectra, using an extinction coefficient of 91 mM −1 cm −1 at 450 nm (Omura and Sato 1964) . Absorption spectra showing substrate binding by the characteristic blue shift in the Soret band were recorded using 0.18 nmol ml −1 CYP102A2 in 500 μl of 50 mM potassium phosphate buffer (pH 7.5) and 20 μl of 5 mM oleic acid in dimethylsulfoxide (DMSO) and 50 mM potassium phosphate buffer as a reference.
Substrate screening
For substrate screening, NADPH oxidation was measured by tracking the absorption decrease at 340 nm with an UV/ vis spectrometer. A solution containing 915 μl of potassium phosphate buffer (pH 7.5), 10 μl of 0.3 mM substrate solution in DMSO and 50 μl of enzyme solution (c=0.8 nmol ml −1 ) was incubated for 5 min in a cuvette. The reaction was started by adding 75 μl of 10 mM NADPH solution. The reaction was monitored for 10 min.
For determination of kinetic parameters, a substrate concentration range of 20-500 μM was used. To enhance substrate solubility, 1 mM cholic acid was added to the reaction buffer. All values were determined at least in triplicates. The data were fitted to the Michaelis-Menten equation by linear regression.
Cytochrome c test Reductase activity was determined by performing the standard cytochrome c assay in microtitre plates using a microtitre plate UV/vis spectrometer (Spectra max 340; Molecular Devices, Germany). Then, 160 μl of a 3 nM CYP102A2 solution in 50 mM potassium phosphate buffer (pH 7.5) and 20 μl of a cytochrome c solution (c=0.75 mg ml −1 to c=6.0 mg ml
) in the same buffer were added to each well. The reaction was started by adding 20 μl of 1 mM NADPH solution.
Activity and stability of CYP102A2
For determination of thermostability, the enzyme samples were incubated at different temperatures between 0°C and 60°C for 30 min. The residual activity was determined using the NADPH oxidation assay as described above. Reductase domain stability was determined by measuring the fluorescence signal (excitation at 470±6 nm, emission at 510±5 nm) of enzyme samples preincubated at the respective temperatures. As the FAD and FMN fluorescence signals are quenched within the intact reductase, emission is only detectable when the apoprotein is formed by release of FAD and FMN. Optimal reaction conditions in terms of pH value and temperature were determined by monitoring the NADPH oxidation, with linoleic acid as substrate.
Long-term operational stability was measured using an ultrafiltration cell (model 8050; Amicon, Lexington, USA) equipped with a regenerated cellulose membrane (cut-off 50 kDa). Then, 0.3 nmol of CYP102A2 in reaction buffer [0.3 μM 12-p-nitrophenoxydodecanoic acid (12-pNCA), 0.5 mM NADPH, 2% DMSO in 1.2 ml of 50 mM potassium phosphate buffer (pH 8.1)] were added and the mixture was stirred gently. Samples of 1 ml were taken every 30 min. The removed volume was replaced by reaction buffer. The conversion of 12-pNCA was determined by measuring the absorption of p-nitrophenolate at 410 nm (Schwaneberg et al. 1999 ).
CYP102A2-catalysed reactions and product derivatisation
Reaction solutions containing 700 μl of 4 μM CYP102A2, 200 μl of 100 mM substrate in DMSO, 8 ml of 50 mM phosphate buffer (pH 7.5) and 1 ml of 3 mM NADPH were stirred carefully at room temperature for 30 min. After addition of another 1 ml of 3 mM NADPH solution, the reaction was continued for a further 30 min. The solution was then acidified to pH 2-3 with dilute hydrochloric acid and extracted thrice with diethyl ether. The combined organic layers were dried over magnesium sulphate and the solvent was evaporated in vacuo. The residue was dissolved in 300 μl of a 1:1 mixture of pyridine/N,O-bis(trimethylsilyl)trifluoroacetamide and 1% trimethylchlorosilane. The solution was transferred into a glass vial and incubated at 75°C for 30 min to yield trimethylsilylated products.
Product identification
Product analysis was carried out by GC/MS (Shimadzu GCMS-QP2010, FS-Supreme-5 column length 30 m, internal diameter 0.25 mm, film thickness 0.25 μm) using helium as carrier gas. Mass spectra were collected using electron ionisation. The column oven was programmed as follows: 200°C for 1 min, rising by 10°C min −1 to 275°C. Product distribution and educt turnover were calculated from the peak area ratios. 
Results
Cloning and overexpression of CYP102A2
The cyp102A2 gene was amplified from B. subtilis genomic DNA by PCR, using oligonucleotides designed to introduce BamHI and SacI restriction sites. The cyp102A2 gene was cloned into a pET28b+ vector, resulting in the expression plasmid pET28CYP102A2. The CYP102A2 monooxygenase with N-terminal His 6 -tag was heterologously expressed in E. coli BL21 (DE3) cells. Optimisation of the expression protocol by altering temperature, shaking speed, cultivation time and the concentration of inducer (IPTG) led to the expression of approximately 40 mg l −1 CYP102A2. Analysis of enzyme production in BL21 (DE3) cells by SDS-PAGE clearly revealed a band with the expected size of approximately 120 kDa. For standard enzyme production, the protocol described in the Materials and methods was used. CYP102A2 was purified on a Ni-NTA affinity resin using the facility of a His 6 -tag and subsequent dialysis procedure ( Table 1 ). The protein recovery after purification was 32%. SDS-PAGE analysis revealed a thick protein band corresponding to our target protein at 120 kDa ( Fig. 1) and minor impurities. However, the amount of CYP102A2 calculated from CO difference spectra with respect to the total protein concentration was only 28%. This can be explained by imidazole inhibition of the heme domain, which leads to a 30% inactivation of CYP102A2 detected by CO difference spectra, even after dialysis against 50 mM potassium phosphate buffer. Besides that, not enough heme was produced and incorporated into the protein during expression. This was proved by a 30% increase in CYP102A2 measured in CO difference spectra, when 0.5 mM of the heme-precursor δ-aminolevulinic acid was added to the culture medium.
Characterisation of recombinant CYP102A2 monooxygenase
The protein was first examined by UV-vis spectroscopy (Fig. 2) , which revealed the typical characteristics of P450, a heme Soret band at 418 nm (low spin) in the absence of substrate, which shifted to 392 nm (high spin) upon the addition of oleic acid. The broad absorbance shoulder between 450 nm and 510 nm is characteristic for a flavincontaining reductase domain. Addition of NADPH to the enzyme solution resulted in the disappearance of this shoulder, due to flavin (FAD, FMN) reduction. The spectrum of the dithionite-reduced and CO-bound form showed the well known absorption maximum at 449 nm.
Both NADPH and NADH were tested as possible electron donors. Cytochrome c reduction using NADPH was much faster than with NADH. In all further experiments, NADPH was used as an electron donor. The reductase activity of CYP102A2 towards cytochrome c (4,180 min −1 ) was higher than that reported for CYP102A1 (2,900 min
; Miles et al. 1992) , whereas the affinity was lower (K M =28.5±5.0 μM for CYP102A2, K M =12.0±3.0 μM for CYP102A1; Noble et al. 1999) . Several classes of substrate, e.g. fatty acids, esters of fatty acids, alkanes, cycloalkanes, aromatic compounds and polycyclic aromatic compounds, were tested as potential substrates of CYP102A2 (Table 2 ). For initial substrate screening, NADPH oxidation at 340 nm was measured. The only substrates found by this test were saturated and unsaturated fatty acids. Steady-state kinetic measurements revealed an unusual behaviour of CYP102A2 towards saturated fatty acids. Although turnover rates for myristic and palmitic acid were comparable with those of oleic and linoleic acid, the affinity of saturated fatty acids to the enzyme was extremely poor: K M values were 40-to 200-fold higher than for unsaturated fatty acids (Table 3) . High standard deviations for kinetic parameters were observed with saturated fatty acids and might be explained by co- (Fig. 3a) . In the case of unsaturated fatty acids as oleic acid, a typical hyperbolic profile, corresponding to Michaelis-Menten kinetics, was observed (Fig. 3b) . Saturated fatty acids with carbon chain lengths less than C12 were not converted by CYP102A2. Lauric acid was hydroxylated by CYP102A2 with very low activity, which was difficult to quantify. The odd-chain fatty acid tridecanoic acid was hydroxylated, with a turnover rate of 15% compared with its even-chain higher homologue, myristic acid (Fig. 4) , but pentadecanoic acid turnover was nearly even with palmitic acid; and heptadecanoic acid was oxidised much faster than stearic acid. The turnover rate of myristic acid hydroxylation was the highest among the saturated fatty acids. Activity of the enzyme towards saturated fatty acids decreased gradually with higher carbon chain lengths.
The enzyme was unexpectedly active at high temperatures. Although isolated from a mesophilic soil bacterium, the enzyme showed highest activity at 51°C, even though its stability was dramatically reduced at this temperature. Incubation for 30 min at 31°C and 49°C resulted in 61% and 17% residual activity, respectively. Incubation at 60°C led to total inactivation of the monooxygenase. The contribution of the reductase domain to the loss of activity was monitored by measuring the fluorescence emission of liberated FAD/FMN, which started at 30°C and increased linearly until 60°C. Activity of CYP102A2 was highest at pH 7.0. Operational stability of CYP102A2 was determined using a simple model of an enzyme membrane reactor, as described in the Materials and methods. + for oleic acid. Conversion of oleic acid, myristic acid and pentadecanoic acid by CYP102A2 led to subterminal hydroxylation of the substrates, as confirmed by GC/MS analyses. The chromatograms of myristic acid and oleic acid reaction extracts showed a similar product distribution of ω-1 to ω-3 hydroxylated fatty acids (ratio ω-1:ω-2:ω-3 approx. 1:2:1). For pentadecanoic acid, equal amounts of the three regioisomeric products were found. Interestingly, CYP102A1 hydroxylated fatty acids preferably at ω-1 position. This fact can be explained by a structural discrepancy of the active sites and the substrate access channels of the two enzymes (see Discussion).
Discussion
CYP102A2 from B. subtilis was successfully cloned, expressed in E. coli and purified via IMAC. The physical properties and substrate spectrum of the enzyme were studied. The optimum temperature of 51°C proved surprisingly high, but the protein was rapidly inactivated at elevated temperatures. Due to the high amino acid sequence homology to CYP102A1 and CYP102A3, both fatty acid hydroxylases, it is not surprising that CYP102A2 also catalysed the conversion of fatty acids to their ω-3, ω-2 and ω-1 hydroxylated products. Evenand odd-chain as well as unsaturated fatty acids (myristic, pentadecanoic, oleic acids) were all exclusively hydroxylated at positions ω-3, ω-2 and ω-1.
Comparing both the amino acid sequences of CYP102A1 and CYP102A2 and their structures [homology model of CYP102A2 generated with SWISS-PROT (Peitsch 1995; Guex and Peitsch 1997; Schwede et al. 2003) , compared with the crystal structure of CYP102A1 (Ravichandran et al. 1993; Li and Poulos 1997) ] revealed some differences within the substrate access channel, which might explain the different regioselectivity and kinetic constants found for CYP102A2 (Fig. 5) . Arginine R47, located at the entrance of the active site of CYP102A1 interacts with the carboxylate group of the fatty acid substrate (Li and Poulos 1997) . As shown by mutagenesis experiments at R47 and Y51 (Ost et al. 2000) , both residues are crucial for the proper positioning of the substrate. In CYP102A2, residue 48 (homologous to R47 in CYP102A1) is glycine, which rules out a direct effect on substrate binding. Our structural model of CYP102A2 leaves room to speculate that, instead, residue R353 might position the substrates, although in a weaker manner than the R47/Y51 couple of CYP102A1, as the stabilising hydrogen bond from tyrosine is missing. This model can explain the higher K M values of CYP102A2 as compared with CYP102A1 towards identical substrates. However, mutagenesis experiments are clearly required to substantiate this hypothesis. Further investigations of this interesting novel P450 monooxygenase are now in progress. This includes the screening of mutants, obtained by sitedirected mutagenesis and directed evolution. , as measured for myristic acid)
